サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1455746

ダイエットピルの世界市場-2023年～2030年

Global Diet Pills Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 240 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.49円
ダイエットピルの世界市場-2023年～2030年
出版日: 2024年03月26日
発行: DataM Intelligence
ページ情報: 英文 240 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界のダイエットピル市場は、2022年に33億4,000万米ドルに達し、2023-2030年の予測期間中にCAGR 6.8％で成長し、2030年には56億5,000万米ドルに達すると予測されています。

ダイエットピルは、肥満症例の増加により市場で絶大な人気を博しています。体重過多と肥満は、大人と子供の大きな問題となっています。World Health Statistics 2023によると、2022年には肥満に悩む5歳未満の子供が約3,700万人いることが確認されています。小児肥満は、子どもが大人になるにつれて、早死や身体障害につながる可能性があります。

人々の健康意識の高まりは、減量のためのアプローチを増加させています。Weight-Loss Statistics 2023によると、約40％の人が体重を減らすためにダイエットを避けており、約30％の人が体重増加を防ぐためにダイエットをしたいと考えています。体重管理におけるダイエットピルの利便性と有効性が、世界の人気を牽引しています。

FDAやその他の組織による減量薬の承認の増加は、市場の成長を積極的に促進します。例えば、2021年にはWeglovyブランドのSemaglutideが成人の過体重と肥満の治療薬としてFDAに承認されました。北米の高いプロモーション活動と新製品開拓は、世界市場の1/3にシェアを拡大しています。

ダイナミクス

肥満の有病率の増加

座りがちなライフスタイルの人々は、糖分や脂肪分の多い加工食品を食べざるを得ないです。多忙なスケジュールの中で、人々はすぐに食べられる食品を選ぶようになっています。カロリーの高い食品の消費が増え、運動量が減ることで、肥満などの生活習慣病の有病率が高くなります。加えて、働く人々はストレスや睡眠不足など、肥満の原因のひとつであるさまざまな状態に見舞われています。

World Obesity Federation 2023は、肥満症例が急速に増加しており、今後12年間で世界人口の半数以上が肥満や過体重に対処する可能性があると予測しています。人々の健康意識の高まりは、体重を減らし、健康な体を提供できる製品の市場を牽引しています。体重を減らすためのダイエットピルの助けは、市場の大きな原動力となる可能性があります。

減量のための栄養補助食品利用の増加

NIHによると、米国成人の約15％が減量のための栄養補助食品を使用するよう登録されています。このうち女性は21％、男性は10％です。栄養補助食品は、錠剤、カプセル、粉末など様々な形態で入手可能なため、その拡大機会を後押ししています。

食欲を抑え、代謝を高める栄養補助食品の機能性は、脂肪燃焼による体重管理にプラスに働く。市場に投入される新製品数の増加が消費者の関心を集めています。例えば、2023年7月、減量サプリメント・ブランドのHydroxycutは、新製品ライン「Hardcore」を発表しました。この製品ラインは、カプセル、グミ、ドリンクスティックで構成されています。

副作用の懸念

ダイエットピルは減量に役立つかもしれないが、いくつかの副作用を引き起こす可能性があります。下痢、ガス、胃痛など、胃腸障害はダイエットピルの最も一般的な副作用です。減量剤は、肝臓や腎臓に深刻な健康問題を引き起こす可能性があることも確認されています。また、甲状腺がんのリスクを高めたり、血糖値を下げる可能性もあります。このようなダイエットピルの生命を脅かす副作用は、市場規模の拡大を妨げるため、人々の使用を心配させています。

また、ダイエットピルは、製品化するまでに数回の試作が必要であり、そのため、より多くの投資が必要となる可能性があります。また、組織や政府によるダイエットピルの承認に関する厳しい規制は、市場のビジネスを妨げる可能性があります。米国FDAは、安全性への懸念を考慮し、いくつかの減量薬を制限または禁止しました。例えば、2023年8月、FDAは、2010年に市場から削除され、そのシブトラミン物質のためにAlfia減量薬を購入しないように主張する公的通知を発表しました。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 肥満の蔓延
      • 減量のための栄養補助食品使用の増加
    • 抑制要因
      • 副作用に関する懸念
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 供給源別

  • 葉
  • 樹皮
  • 果物・野菜
  • 根

第8章 タイプ別

  • 処方薬
  • OTC薬
  • ハーブサプリメント

第9章 形態別

  • 錠剤
  • カプセル
  • 粉末
  • 液体
  • ソフトジェル

第10章 年齢層別

  • 子供
  • 思春期
  • 成人
  • 成人以上

第11章 機能別

  • 薬用
  • アロマ
  • その他

第12章 用途別

  • 減量
  • ボディシェイプ

第13章 流通チャネル別

  • 病院薬局
  • ドラッグストア・小売薬局
  • オンライン薬局

第14章 用途別

  • 食欲抑制
  • 代謝上昇薬
  • 脂肪ブロック
  • その他

第15章 エンドユーザー別

  • 病院
  • 減量センター
  • 家庭

第16章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第17章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第18章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第19章 企業プロファイル

  • Nirvasa
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Applied Nutrition
  • Lovate Health Sciences Inc
  • Chong's Health Care
  • Healthviv
  • MuscleTech
  • Nov-Nordisk A/S
  • Vivus LLC
  • Now Foods
  • Herbal

第20章 付録

目次
Product Code: FB8186

Overview

Global Diet Pills Market reached US$ 3.34 billion in 2022 and is expected to reach US$ 5.65 billion by 2030, growing with a CAGR of 6.8% during the forecast period 2023-2030.

Diet pills are gaining immense popularity in the market due to increasing obesity cases. Overweight and obesity have become a major problem in adults and children. According to World Health Statistics 2023, it is identified that there were around 37.0 million children under five years of age suffering from obesity in 2022. Childhood obesity can lead to premature death and disability as children grow into adults.

Increased health consciousness among people is increasing the approaches for weight loss. According to Weight-Loss Statistics 2023, about 40% of people are avoiding diet to lose weight, and nearly 30% of people are willing to prevent their weight gain. The convenience and effectiveness of diet pills in weight management are driving thier popularity globally.

Increased approvals of weight loss drugs by the FDA and other organizations positively drive market growth. For instance, in 2021, Semaglutide, from the Weglovy brand, was approved by the FDA to treat overweight and obesity in adults. The high promotional activities and new product developments in North America increase its share to 1/3rd of global market.

Dynamics

Growing Prevalence of Obesity

People with sedentary lifestyles are forced to eat processed products high in sugars and fats. With hectic schedules, people are choosing ready-to-eat food products. The increased consumption of food with higher calories and reduced physical activity leads to a high prevalence of lifestyle diseases such as obesity. In addition, the working population are experiencing various condition, such as stress and poor sleep, which are some of the causes of obesity.

The World Obesity Federation 2023 predicts that obesity cases are rapidly increasing, and more than half of the worldwide population might deal with obesity and overweight in the coming 12 years. The rising health consciousness among people is driving the market for products that can reduce their weight and provide a healthy body. The help of diet pills in reducing weight can be a greater driving force for the market.

Increased Use of Dietary Supplements for Weight Loss

According to NIH, approximately 15% of U.S. adults are registered to use weight-loss dietary supplements. Among these, women are reported to use 21 % of pills, while men are subjected to the 10% use. The availability of dietary supplements in various forms, such as tablets, capsules, and powder forms, drives its expansion opportunities.

The functionality of dietary supplements in suppressing the appetite and increasing metabolism positively affects weight management by burning fat. The increased number of new products launched into the market is gaining consumer's attention. For instance, in July 2023, Hydroxycut, a weight-loss supplements brand, introduced its new product line, Hardcore. This line range products comprises capsules, gummies and drink sticks.

Concerns About Side Effects

The diet pills may help weight loss but can cause several side effects. Gastrointestinal problems are diet pills' most common side effects, including diarrhoea, gas and stomach ache. It is also observed that weight loss pills can lead to severe health issues in the liver and kidneys. Such pills may increase thyroidal cancer risk and may lower blood sugar levels. Life-threatening side effects of such diet pills are making people worried about using them, hindering the market size expansion.

The diet pills need to go through several trials before finalizing the product, which may need more investments in them. In addition, the strict regulations about diet pill approvals from organizations and governments can hamper the market business. Considering the safety concerns, U.S. FDA restricted or banned several weight loss pills. For instance, in August 2023, the FDA released a public notification claiming not to purchase Alfia weight loss pills due to its sibutramine substance, that is removed from the market in 2010.

Segment Analysis

The global diet pills market is segmented based on source, type, form, age group, function, usage, distribution channel, application, end-user and region.

Increased Health Awareness

The global diet pills market is segmented based on weight loss and body-shaping usage. This market's weight loss pills segment is gaining immense popularity among teenagers and adults, leading to a larger share of this segment. The rising health concerns of being overweight such as high blood pressure, type 2 diabetes and heart problems, encourage people to take action to lose weight, driving the segment growth.

According to Weight-Loss Statistics 2023, about 40% of people are avoiding diet to lose weight, and just under 30% of people are willing to prevent their weight gain. The rising number of people willing to lose weight and use diet pills to reduce their weight positively impacts the segment's growth. In addition, the new product launches from the key market players in the weight loss category increase the segment demand.

Geographical Penetration

Increased Obesity Cases

North America held the largest share of the global diet pills market. The increased self-awareness about weight management is the key factor driving the market in this region. The increased employment-population ratio of this region has a greater influence on their food patterns. The hectic lifestyles of people increased their consumption of processed food products.

The unhealthy lifestyle of people of this region has led to increased obesity. According to the Centers for Disease Control and Prevention 2023, United States has around 41.9% of adults and 19.7 % of children suffering from obesity. The increased prevalence of obesity and the increase in people's awareness about weight loss drive this region's diet pills market growth.

According to UNC Gillings School of Global Public Health 2021, about 34% of Americans willing to lose weight have used weight loss supplements. The stronger influence of social media on people's lifestyles and more importance for body shape maintenance may positively affect the diet pills market as people are willing to adopt diet pills to lose weight.

Competitive Landscape

The major global players in the market include Nirvasa, Applied Nutrition, Lovate Health Sciences Inc, Chong's Health Care, Healthviv, MuscleTech, Nov- Nordisk A/S, Vivus LLC, Now Foods and Herbalife.

COVID-19 Impact Analysis

The outbreak of COVID-19 had a mixed impact on the global diet pills market. The strict government regulations restricted people to their houses. The increased time for cooking in the pandemic period increased people's food intake. There is increased consumption of processed food products due to their convenience. The high calories and fats of such food products increase the prevalence of obesity.

According to NIH, there is an increased prevalence of obesity among 2 to 20-year age groups during lockdowns. People were not allowed outside their houses, decreasing their physical activity. The shutdown of gyms and exercise centers made it difficult for people to lose weight, giving rise to diet pills. The high food consumption and decreased physical activity, increased the demand for diet pills as people started their weight management.

Further, the pandemic gave rise to e-commerce sector activities. Most people started using online platforms for their necessary purchases. The accessibility and popularity of the e-commerce sector and the wide availability of diet pill products in online platforms increased the market demand. The halted supply chain activities and distribution channel processes created a little disturbance in the diet pills market.

Russia- Ukraine War Impact

The Russia-Ukraine war had a negative impact on many industrial sectors, including food support and services sector. The labor shortage and a lack of resources for the production and distribution of diet pills badly impacted the market. The supply chain and distribution channels were negatively affected, decreasing market growth.

War decreased people's affordability to high-priced products like diet pills. The war created import and export trade disruptions, resulting in product haltation in reach to target customers. The high taxes and increased prices of commodities created economic disturbances. The trade The political and economic uncertainty created due to the war had a negative impact on the diet pills market.

By Source

  • Leaves
  • Barks
  • Fruits and Vegetables
  • Roots

By Type

  • Prescription
  • Over the Counter Drugs
  • Herbal Supplements
  • Others

By Form

  • Tablets
  • Capsules
  • Powder
  • Liquid
  • Softgels

By Age Group

  • Children
  • Adolescents
  • Adults
  • Over Adults

By Function

  • Medicinal
  • Aroma
  • Others

By Usage

  • Weight Loss
  • Body Shaping

By Distribution Channels

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Application

  • Appetite Suppression
  • Metabolism Raising Pills
  • Fat Blocking
  • Others

By End-User

  • Hospitals
  • Weight Loss Centers
  • Home Use

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In July 2023, a Denmark-based global healthcare company, Novo Nordisk, introduced its weight loss drug Wegovy in Germany.
  • In May 2023, Noom, a U.S.-based weight loss startup, unveiled a program prescribing new weight-reducing drugs like Wegovy.
  • In November 2022, a U.S.-based Audax Private Equity, announced the acquisition, of Medi-Weightloss, Inc., a weight-loss and diet pills offering company. This acquisition helps the Medi-Weightloss company to expand its business range.

Why Purchase the Report?

  • To visualize the global diet pills market segmentation based on source, type, form, age group, function, usage, distribution channel, application, end-user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of diet pills market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global diet pills market report would provide approximately 109 tables, 121 figures and 240 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1.Methodology and Scope

  • 1.1.Research Methodology
  • 1.2.Research Objective and Scope of the Report

2.Definition and Overview

3.Executive Summary

  • 3.1.Snippet by Source
  • 3.2.Snippet by Type
  • 3.3.Snippet by Form
  • 3.4.Snippet by Age Group
  • 3.5.Snippet by Function
  • 3.6.Snippet by Usage
  • 3.7.Snippet by Distribution Channels
  • 3.8.Snippet by Application
  • 3.9.Snippet by End-User
  • 3.10.Snippet by Region

4.Dynamics

  • 4.1.Impacting Factors
    • 4.1.1.Drivers
      • 4.1.1.1.Growing Prevalence of Obesity
      • 4.1.1.2.Increased Use of Dietary Supplements for Weight Loss
    • 4.1.2.Restraints
      • 4.1.2.1.Concerns About Side Effects
    • 4.1.3.Opportunity
    • 4.1.4.Impact Analysis

5.Industry Analysis

  • 5.1.Porter's Five Force Analysis
  • 5.2.Supply Chain Analysis
  • 5.3.Pricing Analysis
  • 5.4.Regulatory Analysis

6.COVID-19 Analysis

  • 6.1.Analysis of COVID-19
    • 6.1.1.Scenario Before COVID
    • 6.1.2.Scenario During COVID
    • 6.1.3.Scenario Post COVID
  • 6.2.Pricing Dynamics Amid COVID-19
  • 6.3.Demand-Supply Spectrum
  • 6.4.Government Initiatives Related to the Market During Pandemic
  • 6.5.Manufacturers Strategic Initiatives
  • 6.6.Conclusion

7.By Source

  • 7.1.Introduction
    • 7.1.1.Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 7.1.2.Market Attractiveness Index, By Source
  • 7.2.Leaves
    • 7.2.1.Introduction
    • 7.2.2.Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3.Barks
  • 7.4.Fruits and Vegetables
  • 7.5.Roots

8.By Type

  • 8.1.Introduction
    • 8.1.1.Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.1.2.Market Attractiveness Index, By Type
  • 8.2.Prescription
    • 8.2.1.Introduction
    • 8.2.2.Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3.Over the Counter Drugs
  • 8.4.Herbal Supplements

9.By Form

  • 9.1.Introduction
    • 9.1.1.Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 9.1.2.Market Attractiveness Index, By Form
  • 9.2.Tablets
    • 9.2.1.Introduction
    • 9.2.2.Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3.Capsules
  • 9.4.Powder
  • 9.5.Liquid
  • 9.6.Softgels

10.By Age Group

  • 10.1.Introduction
    • 10.1.1.Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.1.2.Market Attractiveness Index, By Age Group
  • 10.2.Children
    • 10.2.1.Introduction
    • 10.2.2.Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3.Adolescents
  • 10.4.Adults
  • 10.5.Over Adults

11.By Function

  • 11.1.Introduction
    • 11.1.1.Market Size Analysis and Y-o-Y Growth Analysis (%), By Function
    • 11.1.2.Market Attractiveness Index, By Function
  • 11.2.Medicinal
    • 11.2.1.Introduction
    • 11.2.2.Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3.Aroma
  • 11.4.Others

12.By Usage

  • 12.1.Introduction
    • 12.1.1.Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 12.1.2.Market Attractiveness Index, By Usage
  • 12.2.Weight Loss
    • 12.2.1.Introduction
    • 12.2.2.Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3.Body Shaping

13.By Distribution Channels

  • 13.1.Introduction
    • 13.1.1.Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 13.1.2.Market Attractiveness Index, By Distribution Channels
  • 13.2.Hospital Pharmacies
    • 13.2.1.Introduction
    • 13.2.2.Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 13.3.Drug Stores & Retail Pharmacies
  • 13.4.Online Pharmacies

14.By Application

    • 14.1.1.Introduction
    • 14.1.2.Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 14.1.3.Market Attractiveness Index, By Application
  • 14.2.Appetite Suppression
    • 14.2.1.Introduction
    • 14.2.2.Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 14.3.Metabolism Raising Pills
  • 14.4.Fat Blocking
  • 14.5.Others

15.By End-User

  • 15.1.Introduction
    • 15.1.1.Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 15.1.2.Market Attractiveness Index, By End-User
  • 15.2.Hospitals
    • 15.2.1.Introduction
    • 15.2.2.Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 15.3.Weight Loss Centers
  • 15.4.Home Use

16.By Region

  • 16.1.Introduction
    • 16.1.1.Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 16.1.2.Market Attractiveness Index, By Region
  • 16.2.North America
    • 16.2.1.Introduction
    • 16.2.2.Key Region-Specific Dynamics
    • 16.2.3.Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 16.2.4.Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 16.2.5.Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 16.2.6.Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 16.2.7.Market Size Analysis and Y-o-Y Growth Analysis (%), By Function
    • 16.2.8.Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 16.2.9.Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 16.2.10.Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 16.2.11.Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 16.2.12.Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 16.2.12.1.U.S.
      • 16.2.12.2.Canada
      • 16.2.12.3.Mexico
  • 16.3.Europe
    • 16.3.1.Introduction
    • 16.3.2.Key Region-Specific Dynamics
    • 16.3.3.Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 16.3.4.Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 16.3.5.Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 16.3.6.Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 16.3.7.Market Size Analysis and Y-o-Y Growth Analysis (%), By Function
    • 16.3.8.Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 16.3.9.Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 16.3.10.Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 16.3.11.Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 16.3.12.Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 16.3.12.1.Germany
      • 16.3.12.2.U.K.
      • 16.3.12.3.France
      • 16.3.12.4.Italy
      • 16.3.12.5.Spain
      • 16.3.12.6.Rest of Europe
  • 16.4.South America
    • 16.4.1.Introduction
    • 16.4.2.Key Region-Specific Dynamics
    • 16.4.3.Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 16.4.4.Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 16.4.5.Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 16.4.6.Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 16.4.7.Market Size Analysis and Y-o-Y Growth Analysis (%), By Function
    • 16.4.8.Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 16.4.9.Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 16.4.10.Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 16.4.11.Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 16.4.12.Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 16.4.12.1.Brazil
      • 16.4.12.2.Argentina
      • 16.4.12.3.Rest of South America
  • 16.5.Asia-Pacific
    • 16.5.1.Introduction
    • 16.5.2.Key Region-Specific Dynamics
    • 16.5.3.Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 16.5.4.Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 16.5.5.Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 16.5.6.Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 16.5.7.Market Size Analysis and Y-o-Y Growth Analysis (%), By Function
    • 16.5.8.Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 16.5.9.Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 16.5.10.Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 16.5.11.Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 16.5.12.Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 16.5.12.1.China
      • 16.5.12.2.India
      • 16.5.12.3.Japan
      • 16.5.12.4.Australia
      • 16.5.12.5.Rest of Asia-Pacific
  • 16.6.Middle East and Africa
    • 16.6.1.Introduction
    • 16.6.2.Key Region-Specific Dynamics
    • 16.6.3.Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 16.6.4.Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 16.6.5.Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 16.6.6.Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 16.6.7.Market Size Analysis and Y-o-Y Growth Analysis (%), By Function
    • 16.6.8.Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 16.6.9.Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 16.6.10.Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 16.6.11.Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

17.Competitive Landscape

  • 17.1.Competitive Scenario
  • 17.2.Market Positioning/Share Analysis
  • 17.3.Mergers and Acquisitions Analysis

18.Competitive Landscape

  • 18.1.Competitive Scenario
  • 18.2.Market Positioning/Share Analysis
  • 18.3.Mergers and Acquisitions Analysis

19.Company Profiles

  • 19.1.Nirvasa
    • 19.1.1.Company Overview
    • 19.1.2.Product Portfolio and Description
    • 19.1.3.Financial Overview
    • 19.1.4.Key Developments
  • 19.2.Applied Nutrition
  • 19.3.Lovate Health Sciences Inc
  • 19.4.Chong's Health Care
  • 19.5.Healthviv
  • 19.6.MuscleTech
  • 19.7.Nov- Nordisk A/S
  • 19.8.Vivus LLC
  • 19.9.Now Foods
  • 19.10.Herbal

LIST NOT EXHAUSTIVE

20.Appendix

  • 20.1.About Us and Services
  • 20.2.Contact Us